NCT04214418View on ClinicalTrials.gov

Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

February 12, 2020

Primary Completion Date

April 11, 2022

Study Completion Date

July 1, 2022

Conditions
Gastrointestinal Cancer
Interventions
DRUG

Cobimetinib

(40-60 mg) orally once daily (morning) on days 1-21 of each 28-day selective small molecule inhibitor for MEK1 and MEK2

DRUG

Hydroxychloroquine

(600mg) orally twice daily on days 1-28 of each 28-day cycle

DRUG

Atezolizumab

840 mg IV on Days 1 and 15 of each cycle humanized IgG1 monoclonal antibody (MAb)

Trial Locations (2)

10032

Columbia University Irving Medical Center, New York

02912

Brown University, Providence

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Columbia University

OTHER

NCT04214418 - Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies | Biotech Hunter | Biotech Hunter